ANGO stock news

AngioDynamics (ANGO) is likely to see an expansion of its already existing VIT product portfolio with the buyout of Eximo Medical. Read more
AngioDynamics (ANGO) keeps fiscal 2020 revenue guidance intact, slashes EPS view. Read more
Q1 2020 AngioDynamics Inc Earnings Call Read more
AngioDynamics (ANGO) delivered earnings and revenue surprises of 100.00% and -2.32%, respectively, for the quarter ended August 2019. Do the numbers hold clues to what lies ahead for the stock? Read more
AngioDynamics (ANGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. Read more
AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. Read more
AngioDyamics (ANGO) gains from solid segmental contributions in fourth-quarter fiscal 2019. Read more

AngioDynamics (ANGO) Lags Q4 Earnings Estimates

12:25pm, Wednesday, 10'th Jul 2019
AngioDynamics (ANGO) delivered earnings and revenue surprises of -3.85% and 3.72%, respectively, for the quarter ended May 2019. Do the numbers hold clues to what lies ahead for the stock? Read more
AngioDynamics (ANGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. Read more
The NAMIC fluid management portfolio sale clears all of AngioDynamics' (ANGO) outstanding debt. Read more
AngioDynamics' (ANGO) pilot study is intended to support the approval of a future PMA in the United States. Read more
AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. Read more

Proudly made at

ROCKIT